SECUTITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
SCHEDULE 13G
Under the Securities Exchange Act of 1934
Vasogen Inc.
----------------
(Name of Issuer)
Common Shares, without par value
---------------------------------
(Title of Class of Securities)
92232F 10 3
--------------
(CUSIP Number)
July 2, 2003
------------
(Date of Event Which Requires Filing of this Statement)
Check the appropriate box to designate the rule pursuant to which this Schedule
is files:
[ ] Rule 13d-1(b)
[X] Rule 13d-1(c)
[ ] Rule 13d-1(d)
* The remainder of this cover page shall be filled out for a reporting person's
initial filing on this form with respect to the subject class of securities, and
for any subsequent amendment containing information which would alter the
disclosures provided in a prior cover page.
The information required in the remainder of this cover page shall not be deemed
to be "filed" for the purpose of Section 18 of the Securities Exchange Act of
1934 ("Act") or otherwise subject to the liabilities of that section of the Act
but shall be subject to all other provisions of the Act (however, see the Notes)
CUSIP No. 92232F 10 3
1) Names of Reporting Persons: Quest Diagnostics Incorporated
I.R.S. Identification Nos. of Above Persons (entities only): 16-1387862
2) Check the Appropriate Box if a Member of a Group (See Instructions)
(a)
(b)
3) SEC Use Only _____________________________________________
4) Citizenship or Place of Organization: Delaware
_______________________________________________________________________________
Number of Shares (5) Sole Voting Power: 3,682,020
Beneficially Owned by _____________________________________________________
Each Reporting Person (6) Shared Voting Power: 0
With _____________________________________________________
(7) Sole Dispositive Power: 3,682,020
_____________________________________________________
(8) Share Dispositive Power: 0
_______________________________________________________________________________
9) Aggregate Amount Beneficially Owned by Each Reporting Person: 3,682,020
10) Check if the Aggregate Amount in Row (9) Excludes Certain Shares
(See Instructions)
11) Percent of Class Represented by Amount in Row 9: 5.9%
12) Type of Reporting Person (See Instruction): CO
Item 1(a) Name of Issuer: Vasogen Inc.
Item 1(b) Address of Issuer's Principal Executive Offices:
2155 Dunwin Drive
Mississauga, Ontario L5L 4M1
Canada
Item 2(a) Name of Person Filing: Quest Diagnostics Incorporated
Item 2(b) Address of Principal Business Office or, if none, Residence:
One Malcolm Avenue
Teterboro, New Jersey 07608
Item 2(c) Citizenship: Delaware
Item 2(d) Title of Class of Securities: Common Shares without par value
Item 2(e) CUSIP Number: 92232F 10 3
Item 3. If this statement is filed pursuant to 'SS''SS' 240.13d-1(b) or
240.13d-2(b) or (c), check whether the person filing is a:
(a) [ ] Broker or dealer registered under section 15 of the
Act (15 U.S.C 78o).
(b) [ ] Bank as defined in section 3(a)(6) of the Act (15 U.S.C 78c).
(c) [ ] Insurance company as defined in section 3(a)(19) of the Act
(15 U.S.C 78c).
(d) [ ] Investment company registered under section 8 of the
Investment Company Act of 1940 (15 U.S.C 80a-8).
(e) [ ] An investment adviser in accordance with
'SS' 240.13d-1(b)(1)(ii)(E);
(f) [ ] An employee benefit plan or endowment fund in accordance with
'SS' 240.13d-1(b)(1)(ii)(F);
(g) [ ] A parent holding company or control person in accordance with
'SS' 240.13d-1(b)(ii)(G);
(h) [ ] A savings association as defined in Section 3(b) of the
Federal Deposit Insurance Act (12 U.S.C. 1813);
(i) [ ] A church plan that is excluded from the definition of an
investment company under section 3(c)(14) of the Investment
Company Act of 1940 (15 U.S.C. 80a-3);
(j) [ ] Group, in accordance with 'SS' 240.13d-1(b)(1)(ii)(J).
Item 4. Ownership
Provide the following information regarding the aggregate number and
percentage of the class of securities of the issuer identified in
Item 1.
(a) Amount beneficially owned: 3,682,020 (including 625,237 shares that
the reporting person has the right to acquire pursuant to a presently
exercisable warrant issued by the issuer)
(b) Percent of class: 5.9% (including the issuance of 9.375 million
common shares in the offering completed by the issuer on July 2, 2003
and including for purposes of this calculation the warrant referred to
in Item 4(a))
(c) Number of shares as to which the person has:
(i) Sole power to vote or to direct the vote: 3,682,020
(ii) Shared power to vote or to direct the vote: 0
(iii) Sole power to dispose or to direct the disposition of:
3,682,020
(iv) Shared power to dispose or to direct the disposition of: 0
Item 5. Ownership of Five Percent or Less of a Class
Not applicable
Item 6. Ownership of More than Five Percent on Behalf of Another Person
Not applicable
Item 7. Identification and Classification of the Subsidiary Which Acquired the
Security Being Reported on By the Parent Holding Company or Control
Person
Not applicable
Item 8. Identification and Classification of Members of the Group
Not applicable
Item 9. Notice of Dissolution of Group
Not applicable
Item 10. Certifications
By signing below I certify that, to the best of my knowledge and
belief, the securities referred to above were not acquired and are not held for
the purpose of or with the effect of changing or influencing the control of the
issuer of the securities and were not acquired and are not held in connection
with or as a participant in any transaction having that purpose or effect.
SIGNATURE
After reasonable inquiry and to the best of my knowledge and belief, I certify
that the information set forth in this statement is true, complete and correct.
Date July 9, 2003
s/ Leo C. Farrenkopf, Jr.
------------------------------------
Leo C. Farrenkopf, Jr.
Vice President and Secretary
STATEMENT OF DIFFERENCES
The section symbol shall be expressed as ...................'SS'